Non-Hodgkin’s Lymphoma - Recruitment Completed In Ofatumumab NHL Pivotal Study
Oct 1st 2008Drug InformationBlood
Genmab A/S (OMX: GEN) announced it has completed recruitment of patients in the pivotal Phase III study of ofatumumab (HuMax-CD20(R)) in rituximab refractory follicular non-Hodgkin’s lymphoma (NHL). Eighty-one patients receiving treatment at the 1000 mg dose level of ofatumumab have been recruited in the study. Data from these patients will be included in the primary efficacy analysis.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
